Please login to the form below

Not currently logged in
Email:
Password:

Adaptimmune

This page shows the latest Adaptimmune news and features for those working in and with pharma, biotech and healthcare.

A look ahead to key trial readouts at ESMO

A look ahead to key trial readouts at ESMO

Looking at some of the new mechanisms on show, Merck/MSD will also have the first clinical results for its STING activator MK-1454, Adaptimmune will have first-in-human results

Latest news

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Deal Watch September 2016 Deal Watch September 2016

    Adaptimmune Therapeutics entered into a collaboration with MD Anderson Cancer Center to develop specific peptide-enhanced affinity receptor T cell immunotherapies in solid and haematological cancers.

  • Deal Watch February 2016 Deal Watch February 2016

    licence, collaboration expanded. 830. Adaptimmune Therapeutics/ GSK. TCR engineered T-cell therapies inc affinity enhanced T-cell immunotherapy targeting NY-ESO-1 (p1/2); 4 other progs and combination studies.

  • Deal Watch table for June 2014 Deal Watch table for June 2014

    526. Adaptimmune/ GSK. Co-development and option. TCR engineered T-cells which target NY-ESO-1 and other targets in oncology (p1/2).

  • Pharma deals during June 2014 Pharma deals during June 2014

    Of course the growth area within oncology is the immunological approach and GSK closed a $350m co-development and option deal with Adaptimmune. ... Adaptimmune develops TCR engineered T-cells and the agreement focuses on co-development around the cancer

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Adaptimmune appoints Lawrence Alleva to its board Adaptimmune appoints Lawrence Alleva to its board

    Adaptimmune appoints Lawrence Alleva to its board. The former PwC partner will also chair its boardaudit committee. ... Adaptimmune has appointed former PwC partner Lawrence (Larry) Alleva to its board of directors as an independent, non-executive

  • Adaptimmune appoints former GSK executives Adaptimmune appoints former GSK executives

    Dr Amado said: “ I am pleased to be joining Adaptimmune at this exciting time. ... Meanwhile Rawcliffe will lead Adaptimmune's financial management and operations functions including compliance and risk management.

More from appointments
Approximately 2 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
wethepeople

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics